Floatz logo

.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio-

Neuromuscular Junction Disease

Fondazione Policlinico Universitario Agostino Gemelli IRCCSSmall moleculePhase 4 / ApprovedDormant
A
84/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
77/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neuromuscular Junction Disease cohort.

Asset / SponsorPhaseRating
Neostigmine
Merck Sharp & Dohme LLC
Phase 4BBB
Rocuronium Ion
Merck Sharp & Dohme LLC
Phase 4BB
Glycopyrrolate
Merck Sharp & Dohme LLC
Phase 4BB
Androstane-3,17-Diol, 16-(1-Methyl-1-Piperidiniumyl)-2-(1-Piperidinyl)-, Diacetate (Ester), (2.Beta.,3.Alpha.,5.Alpha.,16.Beta.,17.Beta.)-
Merck Sharp & Dohme LLC
Phase 4BB
Cisatracurium Ion
Merck Sharp & Dohme LLC
Phase 4BB
Suxamethonium
Merck Sharp & Dohme LLC
Phase 4BB

Same molecule, other indications

.Gamma.-Cyclodextrin, 6A,6B,6C,6D,6E,7F,6G,6H-Octakis-S-(2-Carboxyethyl)-6A,6B,6C,6D,6E,7F,6G,6H-Octathio- is also rated in:

cirrhosis of liverDormant
BB
Indicative · Phase 4
69 / 100
View asset →
respiratory system disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →
morbid obesityDormant
BB
Indicative · Phase 2/3
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →